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CHAPTER 5
TUMOR SIZE DOES NOT PREDICT PATHOLOGICAL 
COMPLETE RESPONSE RATES AFTER PRE-OPERATIVE 












To evaluate in a cohort of superior sulcus tumors (SST) whether even large tumors can 
respond well to chemoradiotherapy and can be sterilized with modest doses of radiotherapy 
(45 - 50 Gy).
Methods
Patients with SST, treated with trimodality therapy at our institution between 2002 and 
2011, who received 45 - 50 Gy radiotherapy, were included. Resection specimens were 
examined for remaining vital tumor cells. The maximum axial and cranio-caudal tumor 
diameters were measured on the radiotherapy planning scan images and reviewed by four 
authors. The primary tumor was contoured by one author and reviewed by a second to 
obtain gross tumor volume (GTV). 
Results
Twelve out of 36 included patients had a pathological complete response (pCR). No significant 
differences were seen in tumor measurements between patients with and without a 
pCR. Logistic regression analysis demonstrated that neither maximum axial diameter, nor 
cranio-caudal diameter or GTV were predictive for pCR. The area under the ROC-curve for 
prediction of pCR was 0.41 (P = 0.45) for maximum axial diameter, 0.39 (P = 0.37) for cranio-
caudal diameter and 0.33 (P = 0.15) for GTV.
Conclusions
Large tumor size or volume near the beginning of induction chemoradiotherapy does not 
preclude a complete pathological response in SST patients.
CHAPTER 5TUMOR SIZE DOES NOT PREDICT PATHOLOGICAL COMPLETE RESPONSE
  67  
INTRODUCTION
Patients with locally advanced non-small cell lung carcinoma (NSCLC) and a large primary 
tumor are at risk of being considered to have incurable disease or excluded from radical-
intent treatment.1,2 We generally consider radical chemoradiotherapy in eligible patients so 
long as the risk of toxicity appears acceptable - absolute tumor size is not used to allocate 
treatment. We decided to test the hypothesis that even large tumors can respond well to 
chemoradiotherapy. We studied superior sulcus tumors (SST), considered a subgroup of 
NSCLC, because patients with operable SST receive induction chemoradiotherapy followed 
by resection. This allowed us to use pathological complete response (pCR), which has been 
correlated with survival, as an objective, clinically meaningful end-point of treatment 
response.3-6 At the same time we also tested the hypothesis that large tumors could be 
sterilized with modest doses of radiotherapy (45 - 50 Gy).
PATIENTS AND METHODS
Patients and treatment
This retrospective study was performed with institutional approval. Patients treated 
between 2002 and 2011 were eligible if, 1) they had a diagnosis of SST and received 
trimodality therapy, 2) 45 - 50 Gy radiotherapy was delivered in our institution, and 3) the 
primary tumor was completely imaged on a radiotherapy planning computed tomography 
(CT) scan. Standard induction chemoradiotherapy was three cycles of full-dose platinum-
based chemotherapy and CT-planned, image-guided, conformal radiotherapy starting with 
cycle 2.7 Patients without disease progression were usually operated on 4 - 6 weeks after 
induction therapy. 
Histopathological examination
The resection specimen underwent histopathological examination for vital tumor cells. 
During initial gross examination of the resection specimen, at least two blocks were taken 
from the tumor area and two from the adjacent lung. Starting in 2008, if vital tumor cells 
were not identified in these blocks then the remainder of the surgical specimen was 
embedded in paraffin and sectioned for further examination.
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Tumor size measurements
The radiotherapy planning CT scan was typically performed within one to two weeks of the 
start of the first cycle of chemotherapy. When the planning CT was respiratory-correlated 
(4-dimensional), then the end-inspiration phase was used. The maximum axial and cranio-
caudal tumor diameters were measured in Centricity RA 600 6.1 (GE Medical Systems, 
USA) with a 65˝ high-definition 1080p plasma display (Panasonic TH-65PF11, Panasonic 
corporation, Osaka, Japan) and simultaneously reviewed by four authors.
Volumetric analysis
The primary tumor was contoured in VelocityAI 2.7.1 (Velocity Medical Solutions, Atlanta, 
Georgia, USA) by one author and reviewed by a second in order to derive the gross tumor 
volume (GTV). Tumor-soft tissue interfaces were contoured using mediastinal window 
settings and for tumor-lung interfaces, additional information was obtained from lung 
window settings. 
Statistical analysis
Statistical analyses were performed using SPSS, version 17.0 (SPSS, Inc., Chicago, IL, USA). 
The Pearson correlation coefficient (R2) was used to describe correlations. To explore if 
tumor size measurements could predict pathological response, size variables were entered 
in a stepwise backward logistic regression analysis using a cut-off value of P < 0.05. Odds 
ratios (OR) were presented with 95% confidence intervals if statistically significant predictors 
were identified. In addition receiver operating characteristic (ROC) curves were used to 
determine the ability of bi-dimensional tumor size and GTV to predict pCR. An area under 
the curve (AUC) approaching 1 indicated perfect discrimination. Pearson’s χ2-test was used 
to compare groups for occurrence of pCR. The Mann-Whitney test was used to compare 
groups for continuous variables. Statistical significance was defined as P < 0.05.
RESULTS
Patient characteristics
Between January 2002 and December 2011, 84 patients with a SST received trimodality 
treatment and 43 had planning scans for radiotherapy at our institution. Six patients 
were excluded because the radiotherapy dose was either 39 (n = 4) or 66 Gy (n = 2). One 
patient was excluded because atelectasis around the tumor did not allow for accurate 
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tumor delineation. This left a total of 36 patients. The median interval between start of 
induction chemotherapy and the planning CT scan was 12 days (range, 1 - 35 days). Patient 
characteristics are summarized in Table 1.
Table 1. Patient characteristics
Characteristic n (%)
Number of patients included 36




















Tumor size and pathological complete response
Of the 36 eligible patients, 12 (33%) had a pCR after induction therapy. The maximal axial 
tumor diameter ranged from 40 - 123 mm, cranio-caudal diameter ranged from 28 - 133 
ml, and gross tumor volume ranged from 20 - 750 ml. Median maximum axial diameter was 
64 mm (range, 36 - 123 mm) for patients with a pCR and 64 mm (range, 40 - 107 mm) for 
patients without a pCR. Median cranio-caudal diameter was 54 mm (range, 30 - 133 mm) 
and 66 mm (range, 28 - 113 mm) for patients with and without a pCR, respectively. Median 
GTV for patients with a pCR was 50 ml (range, 20 - 250 ml) compared with 104 ml (23 - 382 
ml) for patients without a pCR. No significant differences were seen in tumor measurements
between patients with and without a pCR. 
A strong correlation was observed between maximum axial diameter and GTV (R2 = 0.86,
P < 0.001) and cranio-caudal diameter and GTV (R2 = 0.86, P < 0.001). Logistic regression 
analysis demonstrated that neither maximum axial diameter, nor cranio-caudal diameter or 
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GTV were predictive for pCR. The area under the ROC-curve for prediction of pCR was 0.41 
(P = 0.45) for maximum axial diameter, 0.39 (P = 0.37) for cranio-caudal diameter and 0.33 
(P = 0.15) for GTV.
The study population was divided in two groups with values below and above the median 
(small and large tumors, respectively) for the maximum axial diameter (65 mm), cranio-
caudal diameter (62 mm) and GTV (86 ml). For small tumors, a pCR was achieved in seven 
of 19 (36.8%), six of 19 (31.6%), and seven of 13 (53.8%) patients for maximum axial 
diameter, cranio-caudal diameter and GTV, respectively. For large tumors, this was five of 
17 (29.4%), six of 17 (35.3%) and three of 13 (23.1%), respectively. These differences were 
not statistically significant (P = 0.64, P = 0.81 and P = 0.11, respectively). The median interval 
between start of induction chemotherapy and the planning CT scan was 11 (range, 1 - 19) 
days for large tumors and 13 (range, 1 - 35) days for small tumors.
DISCUSSION
These data, from a cohort of patients with superior sulcus tumors who were managed with 
trimodality therapy, show that large tumor size or volume near the beginning of induction 
chemoradiotherapy does not preclude a complete pathological response. This supports the 
hypothesis that even large tumors can respond well to chemoradiotherapy. The data also
demonstrate that even modest radiation doses delivered concurrently with full-dose 
chemotherapy can be effective in large tumors. These findings are strengthened by reports 
that on univariate analysis tumor size does not appear to be a key determinant of prognosis 
after chemoradiotherapy for locally advanced NSCLC and that long-term survival is possible 
in some patients with larger tumors.8,9
We acknowledge potential limitations of the study. For example, the inclusion criteria and 
retrospective design may have resulted in selection bias; there was some variation in the 
timing of the baseline CT scan; we have not assessed patient survival and we have used SST 
as a model for NSCLC. Finally the relatively small size of the study limits the strength of the 
conclusions that can be drawn. Nonetheless, the results are suggestive that size alone should 
not be the deciding factor in whether or not to offer appropriately selected patients radical-
intent treatment. They also highlight the need for better means of predicting treatment 
response and prognosis in patients with locally advanced NSCLC, irrespective of tumor size.
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